CTRI/2020/09/028152已完成不适用
Retrospective, Prescription Event Monitoring (PEM) study of EMROK &/or EMROK – O (Levonadifloxacin)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,500
- 试验地点
- 1
- 主要终点
- Efficacy of EMROK &/or EMROK – O (Levonadifloxacin)
研究概览
简要总结
Wockhardt has designed this Retrospective, PrescriptionEvent Monitoring study of EMROK (LevonadifloxacinIntravenous Injection 800mg/100ml ) & EMROK – O (Levonadifloxacin Tablets 500mg) in real life setting. EMROK andEMROK - O are indicated in adults with ≥18 years of age. Study end points covered will be: Incidencerates of adverse events, Improvement rate, Failure rate, Overall Global Assessment forEfficacy, Overall Global Assessment forSafety, Patient Demographiccharacteristics and Usage of EMROK Treatment.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 90.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients who were prescribed with EMROK or EMROK – O by their treating physicians.
排除标准
- •Not applicable.
结局指标
主要结局
Efficacy of EMROK &/or EMROK – O (Levonadifloxacin)
时间窗: At the end of the study by Overall Global Assessment for Efficacy
次要结局
- Safety of EMROK &/or EMROK – O (Levonadifloxacin)(At the end of the study by Overall Global Assessment for Safety)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
To evaluate the safety and efficacy of Emrok tablet and Emrok Injection by the surveillance study.Other specified bacterial diseases,CTRI/2023/09/057485Wockhardt Ltd2,500
尚未招募
不适用
Prescription Event Monitoring (PEM) for EMROK tablet and InjectionsOther specified bacterial diseases,CTRI/2021/08/035789Wockhardt Ltd1,500
已完成
不适用
Safety Profile of Secotex ® in Patients With Benign Prostatic HyperplasiaProstatic HyperplasiaNCT02245529Boehringer Ingelheim982
已完成
不适用
Real world data of patients across India will be retrospectively collected in this study of Levonadifloxacin.CTRI/2020/09/028152Wockhardt Limited
已完成
不适用
A Prescription-Event Monitoring (PEM) Study of TiotropiumPulmonary Disease, Chronic ObstructiveNCT02196194Boehringer Ingelheim13,891